Phase I randomized clinical trial of VRC DNA and rAd5 HIV-1 vaccine delivery by intramuscular (i.m.), subcutaneous (s.c.) and intradermal (i.d.) administration (VRC 011).

by Mary E Enama, Julie E Ledgerwood, Laura Novik, Martha C Nason, Ingelise J Gordon, LaSonji Holman, Robert T Bailer, Mario Roederer, Richard A Koup, John R Mascola, Gary J Nabel, Barney S Graham, VRC 011 Study Team
Published 2014-01-01

Homologous boosting with adenoviral serotype 5 HIV vaccine (rAd5) vector can boost antibody responses despite preexisting vector-specific immunity in a randomized phase I clinical...

by Uzma N Sarwar, Laura Novik, Mary E Enama, Sarah A Plummer, Richard A Koup, Martha C Nason, Robert T Bailer, Adrian B McDermott, Mario Roederer, John R Mascola, Julie E Ledgerwood, Barney S Graham, VRC 015 study team
Published 2014-01-01

DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial.

by Barney S Graham, Mary E Enama, Martha C Nason, Ingelise J Gordon, Sheila A Peel, Julie E Ledgerwood, Sarah A Plummer, John R Mascola, Robert T Bailer, Mario Roederer, Richard A Koup, Gary J Nabel, VRC 008 Study Team
Published 2013-01-01

Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity

by James J. Steinhardt, Javier Guenaga, Hannah L. Turner, Krisha McKee, Mark K. Louder, Sijy O’Dell, Chi-I Chiang, Lin Lei, Andrey Galkin, Alexander K. Andrianov, Nicole A. Doria-Rose, Robert T. Bailer, Andrew B. Ward, John R. Mascola, Yuxing Li
Published 2018-02-01

Priming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responses.

by Richard A Koup, Mario Roederer, Laurie Lamoreaux, Jennifer Fischer, Laura Novik, Martha C Nason, Brenda D Larkin, Mary E Enama, Julie E Ledgerwood, Robert T Bailer, John R Mascola, Gary J Nabel, Barney S Graham, VRC 009 Study Team, VRC 010 Study Team
Published 2010-02-01

Safety and Immunogenicity of a rAd35-EnvA Prototype HIV-1 Vaccine in Combination with rAd5-EnvA in Healthy Adults (VRC 012).

by Michelle C Crank, Eleanor M P Wilson, Laura Novik, Mary E Enama, Cynthia S Hendel, Wenjuan Gu, Martha C Nason, Robert T Bailer, Gary J Nabel, Adrian B McDermott, John R Mascola, Richard A Koup, Julie E Ledgerwood, Barney S Graham, VRC012 Study Team
Published 2016-01-01

DNA priming for seasonal influenza vaccine: a phase 1b double-blind randomized clinical trial.

by Julie E Ledgerwood, Abbie R Bellamy, Robert Belshe, David I Bernstein, Srilatha Edupuganti, Shital M Patel, Phyllis Renehan, Thad Zajdowicz, Richard Schwartz, Richard Koup, Robert T Bailer, Galina V Yamshchikov, Mary E Enama, Uzma Sarwar, Brenda Larkin, Barney S Graham, VRC 701 study team
Published 2015-01-01

Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in...

by Cristina Carter, Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Grace L Chen, Shital M Patel, Patricia Winokur, Robert Belshe, Cornelia L Dekker, Barney S Graham, Julie E Ledgerwood, VRC 703 study team
Published 2019-01-01

DNA vaccine priming for seasonal influenza vaccine in children and adolescents 6 to 17 years of age: A phase 1 randomized clinical trial.

by Katherine V Houser, Galina V Yamshchikov, Abbie R Bellamy, Jeanine May, Mary E Enama, Uzma Sarwar, Brenda Larkin, Robert T Bailer, Richard Koup, Myeisha Paskel, Kanta Subbarao, Edwin Anderson, David I Bernstein, Buddy Creech, Harry Keyserling, Paul Spearman, Peter F Wright, Barney S Graham, Julie E Ledgerwood, VRC 702 study team
Published 2018-01-01

Phase 1 study of pandemic H1 DNA vaccine in healthy adults.

by Michelle C Crank, Ingelise J Gordon, Galina V Yamshchikov, Sandra Sitar, Zonghui Hu, Mary E Enama, LaSonji A Holman, Robert T Bailer, Melissa B Pearce, Richard A Koup, John R Mascola, Gary J Nabel, Terrence M Tumpey, Richard M Schwartz, Barney S Graham, Julie E Ledgerwood, VRC 308 Study Team
Published 2015-01-01

Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry

by Yen-Ting Lai, Tao Wang, Sijy O’Dell, Mark K. Louder, Arne Schön, Crystal S. F. Cheung, Gwo-Yu Chuang, Aliaksandr Druz, Bob Lin, Krisha McKee, Dongjun Peng, Yongping Yang, Baoshan Zhang, Alon Herschhorn, Joseph Sodroski, Robert T. Bailer, Nicole A. Doria-Rose, John R. Mascola, David R. Langley, Peter D. Kwong
Published 2019-01-01

An avian influenza H7 DNA priming vaccine is safe and immunogenic in a randomized phase I clinical trial

by Adam D. DeZure, Emily E. Coates, Zonghui Hu, Galina V. Yamshchikov, Kathryn L. Zephir, Mary E. Enama, Sarah H. Plummer, Ingelise J. Gordon, Florence Kaltovich, Sarah Andrews, Adrian McDermott, Michelle C. Crank, Richard A Koup, Richard M. Schwartz, Robert T. Bailer, Xiangjie Sun, John R. Mascola, Terrence M. Tumpey, Barney S. Graham, Julie E. Ledgerwood
Published 2017-06-01

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adult...

by Kenneth H Mayer, Kelly E Seaton, Yunda Huang, Nicole Grunenberg, Abby Isaacs, Mary Allen, Julie E Ledgerwood, Ian Frank, Magdalena E Sobieszczyk, Lindsey R Baden, Benigno Rodriguez, Hong Van Tieu, Georgia D Tomaras, Aaron Deal, Derrick Goodman, Robert T Bailer, Guido Ferrari, Ryan Jensen, John Hural, Barney S Graham, John R Mascola, Lawrence Corey, David C Montefiori, HVTN 104 Protocol Team, and the NIAID HIV Vaccine Trials Network
Published 2017-11-01

Mapping Polyclonal HIV-1 Antibody Responses via Next-Generation Neutralization Fingerprinting.

by Nicole A Doria-Rose, Han R Altae-Tran, Ryan S Roark, Stephen D Schmidt, Matthew S Sutton, Mark K Louder, Gwo-Yu Chuang, Robert T Bailer, Valerie Cortez, Rui Kong, Krisha McKee, Sijy O'Dell, Felicia Wang, Salim S Abdool Karim, James M Binley, Mark Connors, Barton F Haynes, Malcolm A Martin, David C Montefiori, Lynn Morris, Julie Overbaugh, Peter D Kwong, John R Mascola, Ivelin S Georgiev
Published 2017-01-01

Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa.

by Walter Jaoko, Etienne Karita, Kayitesi Kayitenkore, Gloria Omosa-Manyonyi, Susan Allen, Soe Than, Elizabeth M Adams, Barney S Graham, Richard A Koup, Robert T Bailer, Carol Smith, Len Dally, Bashir Farah, Omu Anzala, Claude M Muvunyi, Jean Bizimana, Tony Tarragona-Fiol, Philip J Bergin, Peter Hayes, Martin Ho, Kelley Loughran, Wendy Komaroff, Gwynneth Stevens, Helen Thomson, Mark J Boaz, Josephine H Cox, Claudia Schmidt, Jill Gilmour, Gary J Nabel, Patricia Fast, Job Bwayo
Published 2010-09-01

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.

by Martin R Gaudinski, Emily E Coates, Katherine V Houser, Grace L Chen, Galina Yamshchikov, Jamie G Saunders, LaSonji A Holman, Ingelise Gordon, Sarah Plummer, Cynthia S Hendel, Michelle Conan-Cibotti, Margarita Gomez Lorenzo, Sandra Sitar, Kevin Carlton, Carolyn Laurencot, Robert T Bailer, Sandeep Narpala, Adrian B McDermott, Aryan M Namboodiri, Janardan P Pandey, Richard M Schwartz, Zonghui Hu, Richard A Koup, Edmund Capparelli, Barney S Graham, John R Mascola, Julie E Ledgerwood, VRC 606 Study Team
Published 2018-01-01

Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial.

by Susan Zolla-Pazner, Allan C deCamp, Timothy Cardozo, Nicos Karasavvas, Raphael Gottardo, Constance Williams, Daryl E Morris, Georgia Tomaras, Mangala Rao, Erik Billings, Phillip Berman, Xiaoying Shen, Charla Andrews, Robert J O'Connell, Viseth Ngauy, Sorachai Nitayaphan, Mark de Souza, Bette Korber, Richard Koup, Robert T Bailer, John R Mascola, Abraham Pinter, David Montefiori, Barton F Haynes, Merlin L Robb, Supachai Rerks-Ngarm, Nelson L Michael, Peter B Gilbert, Jerome H Kim
Published 2013-01-01

Plasma IgG to linear epitopes in the V2 and V3 regions of HIV-1 gp120 correlate with a reduced risk of infection in the RV144 vaccine efficacy trial.

by Raphael Gottardo, Robert T Bailer, Bette T Korber, S Gnanakaran, Joshua Phillips, Xiaoying Shen, Georgia D Tomaras, Ellen Turk, Gregory Imholte, Larry Eckler, Holger Wenschuh, Johannes Zerweck, Kelli Greene, Hongmei Gao, Phillip W Berman, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Merlin L Robb, Nelson L Michael, Jerome H Kim, Susan Zolla-Pazner, Barton F Haynes, John R Mascola, Steve Self, Peter Gilbert, David C Montefiori
Published 2013-01-01

Surface-Matrix Screening Identifies Semi-specific Interactions that Improve Potency of a Near Pan-reactive HIV-1-Neutralizing Antibody

by Young D. Kwon, Gwo-Yu Chuang, Baoshan Zhang, Robert T. Bailer, Nicole A. Doria-Rose, Tatyana S. Gindin, Bob Lin, Mark K. Louder, Krisha McKee, Sijy O’Dell, Amarendra Pegu, Stephen D. Schmidt, Mangaiarkarasi Asokan, Xuejun Chen, Misook Choe, Ivelin S. Georgiev, Vivian Jin, Marie Pancera, Reda Rawi, Keyun Wang, Rajoshi Chaudhuri, Lisa A. Kueltzo, Slobodanka D. Manceva, John-Paul Todd, Diana G. Scorpio, Mikyung Kim, Ellis L. Reinherz, Kshitij Wagh, Bette M. Korber, Mark Connors, Lawrence Shapiro, John R. Mascola, Peter D. Kwong
Published 2018-02-01